XTX Topco Ltd Buys Shares of 19,628 Castle Biosciences, Inc. (NASDAQ:CSTL)

Key Points

• XTX Topco Ltd has made a new investment in Castle Biosciences, acquiring 19,628 shares valued at approximately $393,000, which represents about 0.07% of the company.
• Castle Biosciences reported a positive EPS of $0.15, exceeding analyst estimates of ($0.51), alongside revenues of $86.18 million for the last quarter.
• The stock has received several revisions from analysts, with price targets decreasing, but an overall average rating of "Buy" and an average target price of $37.00.

XTX Topco Ltd purchased a new position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,628 shares of the company's stock, valued at approximately $393,000. XTX Topco Ltd owned approximately 0.07% of Castle Biosciences at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in CSTL. Allspring Global Investments Holdings LLC lifted its holdings in Castle Biosciences by 2,070.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 217,794 shares of the company's stock worth $4,360,000 after purchasing an additional 207,761 shares during the period. ProShare Advisors LLC acquired a new position in Castle Biosciences during the 4th quarter valued at about $230,000. Deutsche Bank AG increased its stake in Castle Biosciences by 12.5% during the 4th quarter. Deutsche Bank AG now owns 67,667 shares of the company's stock valued at $1,803,000 after buying an additional 7,495 shares during the period. D. E. Shaw & Co. Inc. acquired a new position in Castle Biosciences during the 4th quarter valued at about $2,414,000. Finally, Man Group plc bought a new stake in Castle Biosciences in the fourth quarter worth about $354,000. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on CSTL shares. Scotiabank lowered their target price on Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating on the stock in a research note on Wednesday, May 21st. Wall Street Zen raised Castle Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday. Lake Street Capital lowered their target price on Castle Biosciences from $40.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group lowered their price target on Castle Biosciences from $42.00 to $37.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $37.00.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL traded up $0.43 during trading hours on Wednesday, reaching $19.77. The stock had a trading volume of 1,023,358 shares, compared to its average volume of 467,574. The business's fifty day moving average is $18.41 and its two-hundred day moving average is $20.18. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.69. The company has a market cap of $573.64 million, a price-to-earnings ratio of -56.48 and a beta of 1.09. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $35.84.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.66. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%. The firm had revenue of $86.18 million for the quarter, compared to analysts' expectations of $71.53 million. As a group, research analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.